Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.

ABSTRACT:

Background

A minority subset of immunotherapy patients manifests hyperprogressive disease (HPD), with the disparity in melanoma subtypes yet to be reported. This study aimed to delineate the proportion and prognosis of HPD in patients receiving anti-PD-1 monotherapy and to identify patient with HPD clinical characteristics across melanoma subtypes to inform clinical decision making.

Methods

Utilizing 4 established HPD definitions, the incidence of HPD in patients with advanced melanoma on anti-PD-1 monotherapy was determined. The incidence rates and prognostic abilities of various HPD definitions were compared to elect the most effective one. This facilitated a comparative analysis of subtypes and clinical features between patients with HPD and traditional progression.

Re

SUBMITTER: Zhou L 

PROVIDER: S-EPMC11883154 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature